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Abstract   
Context: In late 2019, COVID-19 launched a pandemic from around Wuhan, 
China. It`s called the SARS-CoV-2 virus which belongs to the corona family 
and it has a lot in common with SARS-CoV-2, but it has been reported to be 
more common.  
Evidence Acquisition: The risk of the virus is high for people with high blood 
pressure and use medication. The reason for this potential and risk for COVID-
19 is an increase in expression in a membrane protein called ACE2. This 
protein is responsible for converting Ang I to Ang1-9 as well as converting 
Ang II to Ang1-7. 
Results: Its pathogenic role is due to its receptor for SARS-CoV-2 and SARS-
CoV. Research has shown that there is a significant link between hypertension, 
Increase the expression and activity of ACE2 and having coronavirus. That`s 
why our goal is to remind people of high blood pressure about the risk of 
developing Covid-19. We studied ACE2 and Covid-19 from a clinical and 
biological point of view. In the following we have shown the position and the 
type of virus connection to ACE2 with the help of protein database. 
Conclusion: In the SARS-Cov-2, there are four structural proteins and several 
non-structural proteins together with capsid can contain positive-stranded RNA 
viruses. Studies have shown that the Spike (S) protein binds strongly to the 
chain E and F with the ACE2 receptor. 
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1. Context 
     COVID-19 is a global challenge that has 
become an unprecedented pandemic. 
Suddenly, the virus spread to all parts of 
Wuhan, China, Asia, conversely the rest of 
the world, consequently the epidemic of the 
new virus soon becomes a global pandemic. 
COVID-19 is also known as SARS-CoV-2, 
moreover World Health Organization 
(WHO) has also named the new virus 2019-
nCoV. The new virus has infected about 2 
million people worldwide with respiratory 
and heart problems. The new Coronavirus is 
spread faster than its two older families. 
The new one (SARS) is the cause of acute 
respiratory syndrome and the second one 
(MERS) is the cause of the Middle East 
respiratory syndrome. However, to date, 
fewer deaths have been reported. However, 
more than 200000 people in different parts 
of the world have died. More than 200 
countries have been affected by the new 
corona virus, nevertheless no definitive 




For coronavirus, a new virus has been 
reported from people without clinical 
symptoms, with mild clinical symptoms and 
acute clinical symptoms. It is important to 
note that in all three cases, they're 
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individuals retained the potential to be 
transferred to another person [6]. Another 
important issue is the two-week-long 
incubation period of the virus, which makes 
it difficult to diagnose quickly. The solution 
proposed today is home quarantine in this 
pandemic, which in itself has many 
difficulties, including the difficulty of 
controlling economic, social and 
psychological problems in society. Every 
one of different ages is more likely to be 
infected with the new corona virus, but with 
significant differences, people over the age 
of 60 are more likely to be infected. Patients 
with a history of immunodeficiency (such 
as cancer patients undergoing 
chemotherapy, people with organ 
transplants, MS patients and people living 
with HIV) [1, 2] and another group of 
people with underlying diseases, such as 
diabetics [3], heart and vascular patients [4], 
as well as people with high blood pressure, 
are more likely develop acute respiratory 
syndrome. Reports indicate that these 
people are in greater need of hospitalization. 
Significantly, patients need more ICU care 
and need longer treatment. The researchers 
found that most deaths were in people with 
a previous history of the disease [5]. 
Research has shown that ACE2 receptor 
binds to COVID-19 in the host cell. The 
ACE2  has previously been reported as a 
receptor for SARS-CoV and MERS-CoV. 
According to the studies on SAR-CoV the 
cause of further complications in the 
respiratory and cardiac systems in the face 
of this virus was reported to be an increase 
in the expression of ACE2 in heart and lung 
patients. It should be noted that people with 
primary hypertension and secondary 
hypertension have a similar position to heart  
and lung problems [6-9]. 
In this study, we will review the clinical and 
biological characteristics of COVID-19 and 
ACE2. The goal is to warn patients with 
high blood pressure, which will increase the 
potential for conflict with COVID-19 to the 
increased expression of ACE2 in this group 
of patients. We also reviewed the protein 
structure and the type of virus binding to the 
receptor, used protein database 
(www.pdb.org). 
 
2. Evidence Acquisition 
2.1. Hypertension 
     Hypertension is a chronic high blood 
pressure that is considered a silent killer. 
High blood pressure is usually 
asymptomatic, consequently it is difficult to 
diagnose and treat. Late diagnosis leads to a 
large number of people with high blood 
pressure today who needs medication to 
control their blood pressure. Countless 
people around the world will have more 
potential for COVID-19 which we will 
discuss below [10, 11]. 
In a brief review, we note that the heart rate 
is effective in high blood pressure and 
causes the blood to move forward and 
toward the flexible walls of the arteries. 
During each stroke, the heart muscle is at 
rest and then the arterial walls return to their 
original position. In this way, the blood can 
move to the tissues of the body. In people 
with hypertension, the pressure inside the 
arteries is so high that at least some of the 
blood vessels are destroyed. In general, 
patients with high blood pressure are 
divided into two categories: Primary 
hypertension, and secondary hypertension 
[12, 13]. 
Factors that play role in primary 
hypertension include age, gender, obesity, 
high cholesterol and triglycerides, have also 
caused of secondary hypertension include 
kidney problems, aortic valve stenosis, 
endocrine disorders, long term use of birth 
control pills, excessive salt intake, smoking 
and alcohol [4, 15]. 
Accordingly, If we accept that hypertension 
will increase the risk of developing SARS-
CoV-2 the above factors can indirectly 
affect the risk of COVID-19. 
 
2.2. Drugs affecting Angiotensin (Ang) 
     Two groups of target drugs are used for 
this study in hypertension patients: 
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1) Angiotensin-Converting Enzyme 
(ACE) inhibitors that can reduce Ang II (a 
substance that constricts and dilates blood 
vessels), as a result your arteries will relax 
and your blood pressure will drop, 
improving your heart function. 
2) Angiotensin II Receptor Blockers 
(ARB) inhibitors that block angiotensin 
instead of reducing angiotensin levels [16, 
17]. 
 
Table 1: Two groups of drugs that affect Angiotensin (www.mayoclinic.org)  
Examples of angiotensin II receptor blockers include: Examples of ACE inhibitors include: 
 Azilsartan (Edarbi), 
 Candesartan (Atacand),  
 Eprosartan Irbesartan (Avapro), 
 Losartan (Cozaar),  
 Olmesartan (Benicar), 
 Telmisartan (Micardis), 
 Valsartan (Diovan 
 Benazepril  
 Captopril.  
 Enalapril  
 Fosinopril.  
 Lisinopril  
 Moexipril.  
 Perindopril.   
 Quinapril  
 
Mayo Clinic; www.mayoclinic.org 
 
2.3. Structure ACE2 
     ACE2 is Mono-Carboxylic peptides and 
is one of the membrane proteins encoded by 
the ACE2 gene on the chromosome. This 
gene is made up 18 Exones which are very 
similar to the Exones of the ACE gene. 
Therefore, the synonym of acetic acid is 
very similar to ACE. Both of these enzymes 
are considered to be extracellular proteins 
that have catalytic properties [18,19]. ACE2 
consisting of 814 amino acids consisting of 
six chains of A, B, C, D, E and F (Figure 1).  
Also, ACE2 have seven domains: First 
domain of 114 amino acids is involved, 
accordingly, is most similar to ACE (chain 
A), which is similar to 6-84 amino acids. 
The second domain consists of two parts, 
which is between 115-139 and 183-222 
amino acid. Third domain consists of 140-
182 amino acids. Forth and fifth domains 
consist of two parts respectively 242-263 
and 512-616 amino acids for forth domain 
and 264-288  and 437-511 for fifth domain. 
Sixth domain consists of 313-436 amino 
acids and seventh domain consist of 617-
742. ACE2 has 17 amino acid in its 
terminal, which are integral and signaling 
sequence for ACE2. Near the end of C 
terminal, there is 22 amino acid with 
hydrophobic properties, moreover are the 
transmembrane sequences of this protein. 
Also, C terminal consists of a cytoplasmic 
domain, compound containing 43 amino 
acids, moreover is a place for 
phosphorylation [20, 21].  
These three domains are not similar for 
ACE2 to ACE, in fact, there are similar 
similarities between 220 amino acids. This 
is similar to glycoprotein domain for 
transmembrane. Many of the functions of 
the different domains of ACE2 still remain 
unknown. The most similarities to zinc-
binding motif have been identified in both 
ACE2 and ACE1 proteins. In total, ACE2 
has eight amino acid cysteine, which has the 
potential to form four disulfide bonds. Six 
of these cysteines are at the end of the N 
and C domain. Another feature of this 
receptor is the presence of seven 
glycosylation sites [18, 22]. 
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Figure 1. Six chains defined for ACE2, importance of the chain E and F in the position of the connectin for Covid19. N: 
N-Acetyl- D- Glucose Amino; Z: Zinc Ion; L: Lysine. 
 
 
Figure 2. Seven Domain defined for ACE2, based on the division of the amino acid sequence classification are also the 
three parts connected to the receptor for Covid19 which is two Domain. The domain is two parts and includes more 
amino acids. In total it has 223 residue. 
 
Briefly, the depends on the Renin 
Angiotensin System (RAS) for ACE. 
Accordingly, RAS is a converter for 
converting Ang I to Ang II with the help of 
ACE. ACE2 plays a key role in converting 
AngI to Ang1-9  as well as converting Ang 
II to Ang1-7. (Ang II + H2O <=> Ang1-7 + 
L-phenylalanine). Also  Ang1-9 can convert 
to Ang1-7 by ACE. As a result, these affect 
ACE2 through Ang1-7 and masR6 on the 
vasodilatory and anti-fibrotic actions [23, 
24]. It is briefly shown in figure 3. 
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     Origin: there are various reports about 
the original origin of this new coronavirus, 
but what has been identified is that it was 
first spend by seafood market workers in 
Wuhan, China. It is likely to lead to the 
transfer of semi, cooked seafood to humans. 
Some reports of bat-to-human transmission 
are primary origin. Moreover, given these 
two possibilities the possibility of genetic 
manipulation and biological attack has not 
yet ruled out, nevertheless the percentage is 
very low, and is no evidence [25, 26]. 
Epidemiology: COVID-19 started with a 
high prevalence epidemic in Wuhan, China, 
on 29 December  2019, consequently 
become a worldwide pandemic that spread 
to all countries [24]. 
To date, there is no known limiting factor 
for new coronavirus. Human-to-human 
transmission is happening. The most likely 
transmission is through direct contact with 
carriers, although transmission from the 
infected surface of the virus is also possible. 
A significant portion of the spread has been 
related to human-to-human transmission 
within the family, friends and working 
communities, as well as reports on medical 
stuff notifications. What is clear is that the 
travel and movement of carriers with 
symptoms and without symptoms has 
contributed to the rapid spread of the new 
coronavirus [27, 28]. 
Genetic studies of SARS-CoV-2 have 
shown that the new virus has two types, S 
and L. L type is the ancestral version and 
has less prevalence, conversely more 
invasion and faster than S type. At the 
beginning of the prevalence of COVID-19, 
L type was predominant but the weakened S 
type was more prevalence [29, 30]. It 
should be noted that in some countries such 
as Italy, Spain, France and Iran more deaths 
were reported than China. Due to the fact 
that the five of onset of the outbreak, the 
peak of the pandemic, the amount and 
quality of the population in different 
geographical areas are different also 
different reports have been sent. Also, due 
to the non-completion of this pandemic. It is 
not possible yet to report for the death rate 
of COVID-19 [27, 31, 32]. 
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Clinical signs: People with COVID-19  
have been reported to have no primary 
clinical symptoms, may mild clinical 
symptoms similar to the common cold, or 
people with acute clinical symptoms 
including respiratory problems. Dry cough 
and fever (T>37.8) are the most prominent 
features of the new coronavirus. It has been 
reported that these symptoms will not go 
away after 5 days and are progressive. 
Noninfectious sore throats have also been 
reported rarely. In acute conditions, drug 
resistant, decreased levels of consciousness 
and hypercapnia hemodynamics instability 
occur [33-35]. 
Diagnosis: The findings show that people 
with COVID-19 have a positive C-reactive 
protein (CRP) and will usually be more than 
100. According to lymphopenia the first 
recommended tests for these people are 
CBC and CRP. It is also important to check 
the Oxygen saturation (SpO2) of the blood 
pressure [36, 37]. These laboratory tests are 
recommended for all people with or without 
clinical symptoms. Moreover, the CXR/CT 
scan is essential for all people who are at 
higher risk or have respiratory [38]. Figure 
3 shows the proposed diagnostic action 
model. Vital signs and laboratory findings 
that can be used to diagnose patients with 
COVID-19 includes: 
• Rspiratory Rate > 24 
• SpO2 < 90 on ambient air 
• Heart Rate >125 beats/min 
• C-Reactive Protein (CRP) >100 
• D-Dimer>10000 ng/ml 
• Progressive Lymphopenia 
• Creatine Phosphokinase (CPK) > 
twice upper limit of normal 
• Elevated Troponin I 
• High Ferritin >300 ug/l 
• Elevated LDH 
In addition to the CT scan the definitive 
diagnosis of COVID-19 is made by testing 
the new coronavirus molecular with RT-
PCR clinical samples for this molecular test 
of the upper respiratory tract include two 
nasopharyngeal swabs, also recommended 
for patients with lower respiratory tract 
sampling include endotracheal aspirin and 
Broncho alveolar lavage [38, 39]. 
 
Figure 4. Para clinical diagnosis pattern for COVID-19 
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Treatment: no definitive treatment or 
preventive vaccine has been reported for 
COVID-19 (2020, Apr 20). As a result, the 
treatment offered to date is limited to 
supportive therapies, including oxygen and 
increasing immunoglobulin G part of the 
treatment is under the influence of antiviral 
drugs and Corticosteroid. Antiviral drugs 
have been suggested in cases like HIV, 
MERS-CoV and SARS-CoV. The 
recommended drug regimen in Iran for 
people with COVID-19 is the use of 
Hydroxyl-Chloroquine or Chloroquine-
Phosphate. Moreover, complementary drugs 
include Lopinavir or Ritonavir and 
Atazanavir or Ritonavir. The American 
food and drug administration and WHO 




     Classification: The coronavirus family 
divides the virus into two subfamilies 
includes: coronaviridea and letrovirinea. In 
the coronavirus family, the virus includes 
four general that cause Alpha-Coronavirus 
and Beta-Coronavirus infections in humans, 
but Gamma-Coronavirus and Delta-
Coronavirus in birds are pathogenic [40]. 
The full classification is shown in figure 2 
of Hoffmann et al`s paper (2020) [8]. 
Structure (Genome and protein): 
COVID-19 is an RNA virus (enveloped and 
positive-stranded RNA virus) with a lipid 
coating that is supported by several 
proteins[22]. RNA length in SARS-CoV-2 
is 29.9 kb but for SARS-CoV is 27.9 kb and 
for MERS-CoV is 30.1 kb[25]. The SARS-
CoV-2 genome has 14 ORF, encoding a 
total of 27 proteins. Two types of structural 
and non-structural proteins are known for 
COVID-19. The  structural protein such as 
glycoprotein called Spike (S), type of 
coating protein called small Envelope (E), 
Matrix (M), Nucleocapsid (N), which is 
encoded at the end of three genomes [38, 
43]  . The end of 5 genome of polyprotein 
pp1a and pp1a/b are encoded by ORF1a and 
ORF 1ab genes. These genes are also 
involved in encoding nonstructural proteins 
like snp7-nsp10 and snp12-snp16. They 
encode a total of 16 non-structural proteins. 
For COVID-19 eight nonstructural proteins 
are also known to be encoded by genes in 
region 3 of the genome (3a, 3b, p6, 7a, 7b, 
8b, 9b and orfl4). Accordingly, some of the 
non-structural protein like 8a, 8b and 3b the 
difference between SARS-CoV-2 with 
SARS-CoV [44]. 
S protein us a hemotrimer that has more 
1200 amino acids per monomer. This 
protein is highly glycosylated and uses the 
peptide sequence sign at the end to reach 
the endoplasmic reticulum. This protein is 
responsible for binding to the ACE2 
receptor (figure 5). In addition to S protein, 
there is a hemagglutinin- esterase (HE) 
dimmer protein in the Beta-coronavirus that 
binds to glycoprotein ACE2 on the host cell  
surface via silicic acid. This protein is 
involved in the proliferation and spread of 
the virus [43, 45].  
N protein is attached to the ring genome and 
is highly phosphorylated. The shape of the 
rosary like of this protein, helps Replicase-
Transcriptase Complex (RTC) and the 
encapsulation of the genome. These are 
possible functions of this protein [41, 46]. 
The lowest amount of structural protein is 
related to E protein. The role of this protein 
in ion transport is to influence the process 
of virus assembly and facilitate virus 
release. Protein is actually referred to as a 
possible ion channel in the virus. What is 
clear is that the role of this virus in the 
pathogenesis process is more important than 
reproduction process [4, 47]. 
The most abundant structural protein in the 
new coronavirus is related to M protein, that 
is member protein, a dimmer and can have 
different structures. This protein binds to 
the nucleocapsid [21, 48]. 
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Figure 5. The green highlight section is related to: A) Chain E, SARS-CoV-2 Receptor Binding Domain; B) Chain F, 
SARS-CoV-2 Receptor Binding Domain, [Used protein database (www.pdb.org)]. 
 
The association of ACE2 with 
hypertension 
     Previous research has shown that the rate 
of ACE2 expression in hypertension 
increases due to the use of inhibitory drugs 
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like ACE and ARB. In general, ACE2 
reduces inflammation and has always been 
considered as a suitable and high potential 
target for the treatment and control of blood 
pressure, diabetes, and pneumonia. The link 
between the increase of ACE2 expression 
and hypertension has been examined in 
previous studies [19, 49]. Also, we refer 
you to study of table 2 in Pates with his 
colleagues in 2014 [19]. 
Long term use of effective drugs in RAS 
has increased the expression of ACE2, 
consequently due to the receptor properties 
of this protein, some viruses such as SARS 
will be the cause of viral infections. This 
effect is accompanied by an increase in 
expression and an increase in activity. The 
pathogenic role of this protein has been 
established and proven to be true for 
chronic hypertension as well as for blood 
balance. It plays a more supportive role in 
primary hypertension with a genetic 
background ACE2. So it should be said that 
ACE2 increases the expression of this 
deficiency, but does not change its activity 
level [50]. However Xia and his colleagues 
(2009) reported transgenic front of 
increased activity of non transgenic [51]. 
This discrepancy can be examined due to 
different types. In recent years, the average 
blood pressure has been rising, so the 
number of secondary hypertension has 
become critical. This failure threatens 
millions of people around the world. No 
adjustment of ACE2 has been reported for 
secondary hypertension [52]. 
Research has shown that in this type of 
hypertension, along with increasing 
expression and activity, we will have an 
increase in ACE2 and this is directly related 
to the time and dosage of blood pressure 
control drugs. All in all, ACE/ACE2 
balance is a center for controlling and 
regulating blood pressure, as a result raises 
blood pressure by upsetting the expression 
[53, 54]. 
 
Relationship between ACE2 and COVID-
19 
     ACE2 is the only known receptor for 
SARS-CoV-2 and SARS-CoV in the study 
[55]. Accordingly,  Zhao et al. found that 
SARS-CoV-2 used ACE2 to enter the cell 
[56]. Specifically, the SARS-CoV-2 binds 
to the second domain of ACE2 via the S 
protein (figure 6). This second domain is in 
E and F chains which contains 223 amino 
acids (figure 7). This bond is a strong 
chemical that is made directly. In this 
connection there is a disulfide bond 
between the cyc162-cyc170. Residues 
involved in the binding of S protein to chain 
E and F, hence are shown in figure 5. 
Research by Van et al. Showed that the 
glutamine394  binds to the lysine31 have a 
critical point. Earlier it was revealed that 
residues close to lysinee31, tyrosine41, and 
residues (82-84 and 357-353) in human 
ACE2, accordingly are important for S 
protein binding in coronavirus. The more 
connection, the more cells become infected 
and this helps the cell cycle [57, 58]. 
From another point of view, the strong 
binding between S protein and ACE2 
interferes with the function of ACE2. As 
mentioned earlier, ACE2 plays an important 
role in controlling blood pressure and heart 
beat. 
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Figure 6. Domain connector, [Used protein database (www.pdb.org)] 
 
Figure 7. The amino acids involved in the binding of the S protein with E and F chain ACE2 receptor for SARS-CoV-2 
 
4. Conclusion 
     High ACE2 expression in hypertension 
patients greatly contributes to the life cycle, 
cellular assembly and genome proliferation 
of COVID-19. Consequently, it seems that 
monitoring of these patients is necessary to 
prevent to COVID-19. Depending on the 
patient`s condition and if possible, a 
medication regimen should be used that has 
the least effect on increasing the expression 
and ACE2 activity. 
During a pandemic and after a pandemic, 
the most important thing is to lower and 
control your blood pressure naturally or 
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with new medications. Controlling blood 
pressure is directly related to a person`s 
lifestyle so lifestyle changes can reduce the 
need for high blood pressure medications. 
We recommended that more research be 
done on drugs that affect ACE/ACE2 
balance, ARB drugs, ACE2 expression and 
activity. Moreover the use of nanoparticles 
based on green chemistry can be a good 
solution. 
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